论文部分内容阅读
伊立替康单药及联合方案在小细胞肺癌(SCLC)的治疗中均显示了良好的抗瘤活性,特别是与顺铂联合在SCLC的一线治疗中较足叶乙甙加顺铂方案明显延长了患者的生存期。但其独特的毒副作用腹泻发生率较高。现对伊立替康治疗小细胞肺癌的疗效及其副作用进行综述。
Both irinotecan monotherapy and combination regimens showed good antitumor activity in the treatment of small cell lung cancer (SCLC), especially in combination with cisplatin compared with etoposide plus cisplatin in first-line treatment of SCLC The patient’s survival period. But its unique side effects of diarrhea, a higher incidence. The efficacy and side effects of irinotecan in the treatment of small cell lung cancer are reviewed.